Skip to content

Study · Randomized controlled trial · n = 9,340 · 2020

4 results

Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.

Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O

Clinical journal of the American Society of Nephrology : CJASN4 Mar 2020Cited by 42 (Europe PMC)

PMID32132141 (opens in a new tab)PMCIDPMC7133133 (opens in a new tab)DOI10.2215/cjn.11881019 (opens in a new tab)PepBankPUB-32132141
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, serious adverse events occurred to the same extent with liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes, serious side effects were about equally common with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious adverse events, liraglutide versus placebo
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    however, they occurred to the same extent in those on liraglutide versus placebo.
    2 context sentences
    Summary · context
    This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER.
    Summary · context
    Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care.
  2. 02HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes and chronic kidney disease, liraglutide reduced the risk of severe hypoglycemia versus placebo.

    In plain wordsIn adults with type 2 diabetes and kidney disease, liraglutide lowered the risk of severe low blood sugar compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSevere hypoglycemia in patients with CKD
    Study

    n = 2,158

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.63 ratio
    severe hypoglycemia, CKD

    Source sentences

    Summary
    Risk of severe hypoglycemia was significantly reduced with liraglutide versus placebo in patients with CKD or with micro- or macroalbuminuria (hazard ratio, 0.63 [95% CI, 0.43 to 0.91] and 0.57 [95% CI, 0.40 to 0.82], respectively).
    2 context sentences
    Summary · context
    This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER.
    Summary · context
    Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care.
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, no interaction of adverse events with randomized therapy was seen across albuminuria groups.

    In plain wordsIn adults with type 2 diabetes, side effects of liraglutide did not differ by the amount of protein in the urine.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdverse events by albuminuria status
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, no interaction of adverse events with randomized therapy was observed in patients with micro- or macro- versus normoalbuminuria (interaction P=0.11).
    2 context sentences
    Summary · context
    This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER.
    Summary · context
    Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes and micro- or macroalbuminuria, liraglutide reduced the risk of severe hypoglycemia versus placebo.

    In plain wordsIn adults with type 2 diabetes and protein in the urine, liraglutide lowered the risk of severe low blood sugar compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSevere hypoglycemia in patients with albuminuria
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.57 ratio
    severe hypoglycemia, albuminuria

    Source sentences

    Summary
    Risk of severe hypoglycemia was significantly reduced with liraglutide versus placebo in patients with CKD or with micro- or macroalbuminuria (hazard ratio, 0.63 [95% CI, 0.43 to 0.91] and 0.57 [95% CI, 0.40 to 0.82], respectively).
    2 context sentences
    Summary · context
    This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER.
    Summary · context
    Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.